Potential Role of Insulin Growth-Factor-Binding Protein 2 as Therapeutic Target for Obesity-Related Insulin Resistance

Evidence from observational and in vitro studies suggests that insulin growth-factor-binding protein type 2 (IGFBP2) is a promising protein in non-communicable diseases, such as obesity, insulin resistance, metabolic syndrome, or type 2 diabetes. Accordingly, great efforts have been carried out to e...

Full description

Saved in:
Bibliographic Details
Published in:International journal of molecular sciences 2021-01, Vol.22 (3), p.1133
Main Authors: Boughanem, Hatim, Yubero-Serrano, Elena M, López-Miranda, José, Tinahones, Francisco J, Macias-Gonzalez, Manuel
Format: Article
Language:English
Subjects:
Amino acids
Binding sites
Bioavailability
Cell adhesion & migration
Cell cycle
Cell growth
Diabetes mellitus (non-insulin dependent)
Diabetes Mellitus, Type 2
epigenetic
Extracellular matrix
Gene expression
Humans
IGFBP2
Insulin
Insulin Resistance
Insulin-Like Growth Factor Binding Protein 2 - metabolism
Insulin-like growth factor-binding protein 2
Insulin-like growth factors
lifestyle modification
Ligands
Lung cancer
Metabolic disorders
Metabolic Syndrome
Molecular structure
Obesity
Obesity - complications
Obesity - metabolism
Physical activity
Physiology
Proteins
Review
Therapeutic applications
Transcription factors
Citations: Items that this one cites
Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:Evidence from observational and in vitro studies suggests that insulin growth-factor-binding protein type 2 (IGFBP2) is a promising protein in non-communicable diseases, such as obesity, insulin resistance, metabolic syndrome, or type 2 diabetes. Accordingly, great efforts have been carried out to explore the role of IGFBP2 in obesity state and insulin-related diseases, which it is typically found decreased. However, the physiological pathways have not been explored yet, and the relevance of IGFBP2 as an important pathway integrator of metabolic disorders is still unknown. Here, we review and discuss the molecular structure of IGFBP2 as the first element of regulating the expression of . We highlight an update of the association between low serum IGFBP2 and an increased risk of obesity, type 2 diabetes, metabolic syndrome, and low insulin sensitivity. We hypothesize mechanisms of IGFBP2 on the development of obesity and insulin resistance in an insulin-independent manner, which meant that could be evaluated as a therapeutic target. Finally, we cover the most interesting lifestyle modifications that regulate IGFBP2, since lifestyle factors (diet and/or physical activity) are associated with important variations in serum IGFBP2.
ISSN:1422-0067
1661-6596
1422-0067
DOI:10.3390/ijms22031133